• Users Online: 321
  • Print this page
  • Email this page
Year : 2020  |  Volume : 3  |  Issue : 5  |  Page : 29-34

Systemic therapy for thoracic malignancies during the COVID-19 pandemic

Department of Medical Oncology, Tata Memorial Centre, HBNI, Mumbai, Maharashtra, India

Correspondence Address:
Nandini Menon
Department of Medical Oncology, Tata Memorial Hospital, E Borges Road, Parel, Mumbai - 400 012, Maharashtra
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/CRST.CRST_110_20

Get Permissions

People with cancer are particularly vulnerable during this pandemic and are at high risk of developing a serious COVID-19-related illness. The data that are available suggest that patients with cancer, especially those who are undergoing treatment, are at a higher risk for severe COVID-19 infection and death. These patients need increased surveillance, screening, and better personal protection strategies. Patients with lung and esophageal cancers often require aggressive multidisciplinary treatment. In the era of the COVID-19 pandemic, we face new challenges in delivering systemic therapies (chemotherapy/targeted therapy/immunotherapy) to patients with thoracic malignancies. This review aims to highlight the common issues faced and measures that need to be taken to effectively deliver systemic therapy to patients with thoracic malignancies.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded95    
    Comments [Add]    

Recommend this journal